Nothing Special   »   [go: up one dir, main page]

IN2014CH00386A - - Google Patents

Info

Publication number
IN2014CH00386A
IN2014CH00386A IN386CH2014A IN2014CH00386A IN 2014CH00386 A IN2014CH00386 A IN 2014CH00386A IN 386CH2014 A IN386CH2014 A IN 386CH2014A IN 2014CH00386 A IN2014CH00386 A IN 2014CH00386A
Authority
IN
India
Prior art keywords
neu
peptide
her2
provides
vaccine composition
Prior art date
Application number
Inventor
Daisuke Asari
Arimichi Okazaki
Kyohei Matsushita
Katsuyuki Okubo
Yoshiki Maeda
takuya Shishido
Wenjing Li
Mitsuhiko Hori
Haruo Sugiyama
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of IN2014CH00386A publication Critical patent/IN2014CH00386A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a cancer vaccine composition for mucosal administration comprising (i) a HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.
IN386CH2014 2013-02-05 2014-01-29 IN2014CH00386A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013020909 2013-02-05

Publications (1)

Publication Number Publication Date
IN2014CH00386A true IN2014CH00386A (en) 2015-04-03

Family

ID=50028739

Family Applications (1)

Application Number Title Priority Date Filing Date
IN386CH2014 IN2014CH00386A (en) 2013-02-05 2014-01-29

Country Status (8)

Country Link
US (1) US20140220079A1 (en)
EP (1) EP2762161A1 (en)
JP (1) JP2014169283A (en)
KR (1) KR20140100418A (en)
CN (1) CN103961700A (en)
CA (1) CA2840978A1 (en)
IN (1) IN2014CH00386A (en)
RU (1) RU2014102948A (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016006245A2 (en) 2013-10-03 2017-08-01 Nitto Denko Corp mucosal vaccine composition
CA2923028A1 (en) 2013-10-03 2015-04-09 Nitto Denko Corporation Mucosal vaccine composition
CA3013713A1 (en) 2015-02-11 2016-08-18 The Johns Hopkins University Bacteria over-expressing c-di-amp and therapeutic methods
JP2020158494A (en) * 2019-03-19 2020-10-01 日東電工株式会社 Oral mucosa-adhering vaccine preparation
CN111840542B (en) * 2020-08-06 2023-09-01 安徽省力瑞投资管理有限公司 Aluminum nanoparticle vaccine adjuvant-delivery system coated with phospholipid bilayer, mono-phospholipid A and cyclic dinucleotide and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
JP4931798B2 (en) 2004-03-15 2012-05-16 ケイ．アール． カラオリス，デイヴィッド Methods for immune, inflammatory or neuroprotective responses
DE102004049223A1 (en) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Preparation for vaccination, vaccination and use of a vaccine preparation
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
JP5635399B2 (en) * 2007-06-01 2014-12-03 ザ ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド Vaccine for prevention of breast cancer recurrence
CN107050440B (en) * 2009-04-01 2021-10-29 迈阿密大学 Vaccine compositions and methods of use thereof
WO2011026111A1 (en) * 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity

Also Published As

Publication number Publication date
RU2014102948A (en) 2015-08-10
CA2840978A1 (en) 2014-08-05
US20140220079A1 (en) 2014-08-07
CN103961700A (en) 2014-08-06
KR20140100418A (en) 2014-08-14
JP2014169283A (en) 2014-09-18
EP2762161A1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
MX2021014956A (en) Subcutaneous formulations of anti-cd38 antibodies and their uses.
IN2014CH00396A (en)
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX371187B (en) Therapeutic peptides.
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
TN2015000396A1 (en) Antibody drug conjugates
MX2019013123A (en) Oral dosing of glp-1 compounds.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2016004570A (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy.
IN2014CH00391A (en)
CY1117214T1 (en) COMPOSITION FOR CONTROLLED OVENTION STUDY
MX2017007595A (en) Immunotherapy for angiogenic disease.
MX2017003211A (en) Anti-met antibodies and compositions.
IN2014CH00393A (en)
IN2014CH00395A (en)
MY191539A (en) Streptococcal vaccine
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2016005285A (en) Conjugates of somatostatin and its analogs.
IN2014CH00386A (en)
BR112017004739A2 (en) follicle stimulating hormone ligands, ligand-gonadotropin complex, use of a binder, and pharmaceutical composition
MX2017010883A (en) Composition for treatment of infertility.
IN2014CH00390A (en)
MX2015012905A (en) Recombinant factor viii formulations.
MX2020005454A (en) Improved treatment of cancer.
NZ725303A (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer